Q-omics provides the consensus-scored TFDP1P2 profile across patient tissues and cancer cell-line models. TFDP1P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, TFDP1P2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TFDP1P2 RNA expression shows 15,073 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ESCA, KIRC, and DLBC as cancer lineages where TFDP1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFDP1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFDP1P2 survival associations across molecular data types. TFDP1P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFDP1P2 RNA expression–survival associations across cancer types. High TFDP1P2 expression shows unfavorable associations in ESCA, ACC, DLBC and THYM, but favorable associations in CESC and BLCA. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify ESCA as the clearest survival context for TFDP1P2 RNA expression.
This table summarizes TFDP1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TFDP1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFDP1P2 shows lower tumor expression in KIRC, KICH, THCA and LIHC and higher tumor expression in BLCA and COAD. The KIRC box plot shows higher TFDP1P2 RNA expression in normal versus tumor tissue (log2 FC = −1.313, t-test p < 0.001).
This table shows molecular features associated with TFDP1P2 in patient tissues and cancer cell lines. In patient samples, TFDP1P2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
